AU2007288129B2 - Recombinant HCV E2 glycoprotein - Google Patents

Recombinant HCV E2 glycoprotein Download PDF

Info

Publication number
AU2007288129B2
AU2007288129B2 AU2007288129A AU2007288129A AU2007288129B2 AU 2007288129 B2 AU2007288129 B2 AU 2007288129B2 AU 2007288129 A AU2007288129 A AU 2007288129A AU 2007288129 A AU2007288129 A AU 2007288129A AU 2007288129 B2 AU2007288129 B2 AU 2007288129B2
Authority
AU
Australia
Prior art keywords
hcv
glycoprotein
modified
binding
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007288129A
Other languages
English (en)
Other versions
AU2007288129A1 (en
Inventor
Heidi Drummer
Kathleen Mc Caffrey
Pantelis Poumbourios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904635A external-priority patent/AU2006904635A0/en
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority to AU2007288129A priority Critical patent/AU2007288129B2/en
Publication of AU2007288129A1 publication Critical patent/AU2007288129A1/en
Application granted granted Critical
Publication of AU2007288129B2 publication Critical patent/AU2007288129B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
AU2007288129A 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein Active AU2007288129B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007288129A AU2007288129B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AU2006904635 2006-08-25
AU2006904635A AU2006904635A0 (en) 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
AU2006906090A AU2006906090A0 (en) 2006-11-01 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906090 2006-11-01
AU2006906282 2006-11-10
AU2006906282A AU2006906282A0 (en) 2006-11-10 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein
AU2007288129A AU2007288129B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein

Publications (2)

Publication Number Publication Date
AU2007288129A1 AU2007288129A1 (en) 2008-02-28
AU2007288129B2 true AU2007288129B2 (en) 2013-03-07

Family

ID=39106399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007288129A Active AU2007288129B2 (en) 2006-08-25 2007-08-24 Recombinant HCV E2 glycoprotein

Country Status (8)

Country Link
US (2) US8535686B2 (enExample)
EP (1) EP2061805B1 (enExample)
JP (2) JP5674310B2 (enExample)
KR (1) KR101500017B1 (enExample)
CN (1) CN101563362B (enExample)
AU (1) AU2007288129B2 (enExample)
CA (1) CA2661814A1 (enExample)
WO (1) WO2008022401A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022401A1 (en) * 2006-08-25 2008-02-28 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2009131681A2 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN102199613A (zh) * 2010-03-25 2011-09-28 国立大学法人东京大学 感染性丙型肝炎病毒高生产hcv突变体及其应用
EP2600894B1 (en) 2010-08-04 2017-02-01 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified hepatitis c virus proteins
WO2012068637A1 (en) 2010-11-26 2012-05-31 The Macfarlane Burnet Institute For Medical Research And Public Health Compositions and methods
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN110049993A (zh) * 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白
EP4003513A4 (en) * 2019-07-26 2023-08-30 The Scripps Research Institute MODIFIED HCV E2 IMMUNOGENS AND ASSOCIATED VACCINE COMPOSITIONS
BR112022023101A2 (pt) * 2020-05-11 2023-01-17 Macfarlane Burnet Institute For Medical Res And Public Health Limited Composição compreendendo uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv para uso no tratamento ou prevenção de infecção por hcv, uso de uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv, e método de tratamento ou prevenção de infecção por hcv
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509421A (pt) 1994-10-21 1997-09-30 Innogenetics Nv Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
EP1326625A4 (en) 2000-09-13 2005-05-04 Hawaii Biotech Inc IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
PL366621A1 (en) * 2001-04-24 2005-02-07 Innogenetics N.V. Core-glycosylated hcv envelope proteins
IL145440A0 (en) 2001-09-13 2002-06-30 Xtl Biopharmaceuticals Ltd Synthetic hcv envelope proteins and their use for vaccination
WO2005067643A2 (en) * 2004-01-07 2005-07-28 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
WO2008022401A1 (en) * 2006-08-25 2008-02-28 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant hcv e2 glycoprotein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORNS, X. et al, "Characterization of Modified Hepatitis C Virus E2 Proteins Expressed on the Cell Surface", Virology, 2000, Vol. 274(1), page 75-85 *
LECHMANN, M & LIANG, T.J., "Vaccine Development for Hepatitis C", SEMINARS IN LIVER DISEASE, 2000, Vol. 20(2), page 211-226 *

Also Published As

Publication number Publication date
EP2061805B1 (en) 2020-02-12
WO2008022401A1 (en) 2008-02-28
CA2661814A1 (en) 2008-02-28
KR101500017B1 (ko) 2015-03-09
US20110014209A1 (en) 2011-01-20
JP2014240427A (ja) 2014-12-25
CN101563362A (zh) 2009-10-21
JP5674310B2 (ja) 2015-02-25
KR20090053930A (ko) 2009-05-28
JP5999524B2 (ja) 2016-09-28
US8535686B2 (en) 2013-09-17
EP2061805A1 (en) 2009-05-27
AU2007288129A1 (en) 2008-02-28
EP2061805A4 (en) 2010-08-04
US20140120127A1 (en) 2014-05-01
US9598467B2 (en) 2017-03-21
JP2010501594A (ja) 2010-01-21
CN101563362B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
AU2007288129B2 (en) Recombinant HCV E2 glycoprotein
JP2010501594A6 (ja) 組換えｈｃｖ ｅ２糖タンパク質
Forns et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV
Heile et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
Alvarez‐Lajonchere et al. Immunogenicity of CIGB‐230, a therapeutic DNA vaccine preparation, in HCV‐chronically infected individuals in a Phase I clinical trial
NZ528952A (en) Particles of HCV envelope proteins: use for vaccination
JP6942309B2 (ja) フラビウイルスウイルス様粒子
CA2125700A1 (en) Hepatitis e virus peptide antigens and antibodies
Goncalvez et al. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses
Fournillier et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization
US9884109B2 (en) Compositions and methods
CA2601400A1 (en) Improvements in or relating to treatment and prevention of viral infections
Kachko et al. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles
Torresi et al. A self‐adjuvanting multiepitope immunogen that induces a broadly cross‐reactive antibody to hepatitis C virus
US20030091590A1 (en) Recombinant rhabdoviruses as live-viral vaccines
WO2002089728A2 (en) Recombinant rhabdoviruses as live-viral vaccines
Naik In vitro infectivity of the Hepatitis C Virus in the context of humoral immunity and immune escape
Vasiliauskaite Structural characterization of viral envelope glycoproteins
Xuan Investigating the Role of Dengue-Specific Immunity in Protection and Disease Using Symptomatic Mouse Models
Walker Characterising viral evolution and the host humoral immune response in early primary HCV infection
Wong Characterization of the Humoral Immune Response Elicited Against a Prophylactic Vaccine Composed of Recombinant Envelope Glycoproteins from Hepatitis C Virus
Migliaccio core| E||| E2| p7|
Dengue Chimpanzee Fab Fragments and a Derived
MXPA97009271A (en) Diagnosis of, and vaccination against, in positive thread rna virus using an isolated polypeptide, do not process
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)